title: Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells.
abstract: Bispecific antibodies (CD3x19) against the CD3epsilon-chain of the T-cell-receptor/CD3 complex and the CD19 antigen on B cells can target polyclonal, nontumor-specific T cells to B lymphoma cells. This induces T-cell activation, and generation of cytotoxic T cells (CTLs). These polyclonal CTLs, targeted by the CD3x19 bispecific antibodies, can lyse CD19(+) B-lymphoma cells. In a xenotransplant model in severe combined immunodeficiency deficient (SCID) mice, we and others observed that CD28 triggering is required for efficient elimination of B-lymphoma cells and cure from the tumor in addition to CD3x19 administration. We also showed that the activation and targeting of CTLs to the target cell by signal one alone, ie, the CD3x19 mab, induces T-cell death by apoptosis. In blocking experiments we showed that this "veto" apoptosis is mediated by the CD95/Fas ligand. Addition of anti-CD28 (signal 2) renders the T cells resistant for veto apoptosis both in vitro and in vivo. We therefore conclude that the role of costimulation in immunotherapy with bispecific antibodies or other T-cell-based immune strategies is not only to facilitate T-cell activation but also to prevent T-cell deletion by apoptosis.
authors.affiliation: Max Delbrück Center for Molecular Medicine, Berlin-Buch, Germany. pdaniel@mdc-berlin.de
authors.forename: P T
authors.initials: PT
authors.lastname: Daniel
authors.forename: A
authors.initials: A
authors.lastname: Kroidl
authors.forename: J
authors.initials: J
authors.lastname: Kopp
authors.forename: I
authors.initials: I
authors.lastname: Sturm
authors.forename: G
authors.initials: G
authors.lastname: Moldenhauer
authors.forename: B
authors.initials: B
authors.lastname: Dörken
authors.forename: A
authors.initials: A
authors.lastname: Pezzutto
mesh_terms: D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D018033:Antibodies, Bispecific / Q000276:immunology* / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis; D018106:CD28 Antigens / Q000276:immunology / Q000378:metabolism*; D053222:Fas Ligand Protein; D006801:Humans; D007114:Immunization; D020287:In Situ Nick-End Labeling; D008213:Lymphocyte Activation / Q000276:immunology; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000628:therapy*; D008562:Membrane Glycoproteins / Q000502:physiology; D051379:Mice; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000502:physiology; D014407:Tumor Cells, Cultured
chemical_list: D000906:Antibodies; D018033:Antibodies, Bispecific; D018106:CD28 Antigens; C505661:FASLG protein, human; D053222:Fas Ligand Protein; C505658:Fasl protein, mouse; D008562:Membrane Glycoproteins